K. Tan

Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients

M. Karsdal, A. Guermazi, M. Crema, 2017, Pain.

Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo

E. Masliah, M. Spillantini, E. Rockenstein, 2019, Neurobiology of Disease.

Efficacy of Oral Collagen in Joint Pain - Osteoarthritis and Rheumatoid Arthritis

P. Chan, T. Woo, A. Gardner, 2017 .

Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies

K. Höglund, R. Narwal, M. Groves, 2015, Journal of Alzheimer's disease : JAD.

EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA-AMYLOID 42 (Aβ42)-SPECIFIC ANTIBODY, IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE

I. Chessell, Nancy Lee, R. Narwal, 2017, Alzheimer's & Dementia.

PRECLINICAL DISCOVERY AND DEVELOPMENT OF MEDI1814, A MONOCLONAL ANTIBODY SELECTIVELY TARGETING BETA-AMYLOID 42 (Aβ42)

I. Chessell, C. Lloyd, R. Narwal, 2017, Alzheimer's & Dementia.